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ABSTRAK 
 
Pengenalan: Pesakit kencing manis berisiko untuk mendapat luka di lapisan epitelium 
kornea, samada berpunca daripada penyakit kencing manis sendiri ataupun selepas 
pembedahan mata seperti vitrektomi. Jangkamasa penyembuhan luka epitelium kornea 
mungkin turut terjejas akibat penyakit kencing manis. Pelbagai bahan telahpun dikaji untuk 
menguji keberkesanannya terhadap penyembuhan luka kornea. Oksigen memainkan peranan 
penting sebagai nutrien untuk tisu badan dalam proses penyembuhan luka. Namun demikian, 
keberkesanan penggunaan oksigen untuk rawatan pemulihan luka kornea tidak diketahui. 
 
Objektif: Kajian ini bertujuan membandingkan jangkamasa penyembuhan luka epitelium 
kornea antara pesakit kencing manis yang menerima atau tidak menerima rawatan oksigen 
selepas pembedahan vitrektomi. Ia juga untuk mengenalpasti samada faktor-faktor seperti 
usia, jangkamasa menghidap kencing manis, jangkamasa pembedahan, tahap pengawalan 
kencing manis serta paras hemoglobin mempunyai pengaruh terhadap jangkamasa 
penyembuhan luka epitelium kornea. 
 
Metodologi: Kajian klinikal secara rawak ini melibatkan pesakit kencing manis yang 
menjalani pembedahan vitrektomi di Hospital Tuanku Ja’afar Seremban dari Oktober 2013 
hingga Oktober 2014. Luka epitelium kornea berbentuk bulat dan berdiameter 6mm dibuat 
semasa pembedahan sekiranya berlaku kekaburan kornea. Selepas pembedahan, pesakit-
pesakit dibahagikan secara rawak kepada dua kumpulan; “Standard” (rawatan lazim dengan 
ubat titis mata Maxitrol™ dan homatropine setiap enam jam) dan “Oxygen” (rawatan lazim 
beserta rawatan oxygen melalui topeng muka, sebanyak 10 liter/minit selama satu jam, setiap 
xi 
 
12 jam sekali untuk tiga hari berturut-turut). Jangkamasa untuk luka kornea sembuh 
sepenuhnya dicatitkan. Parameter lain seperti usia pesakit, jangkamasa kencing manis, 
jangkamasa pembedahan dan paras HbA1C serta hemoglobin turut direkodkan. 
 
Keputusan: Sejumlah 32 mata daripada 32 pesakit terlibat dalam kajian ini, merangkumi 15 
mata dalam kumpulan “Standard” dan 17 mata dalam kumpulan “Oxygen”. Tiada perbezaan 
signifikan didapati antara kedua-dua kumpulan tersebut dari segi demografik pesakit dan 
penyakit. Purata jangkamasa penyembuhan luka epitelium kornea dalam kumpulan rawatan 
oksigen adalah lebih cepat berbanding kumpulan rawatan lazim (3.24 hari berbanding 4.27 
hari, p = 0.040). Analisa regresi menunjukkan tiada hubungkait antara jangkamasa 
penyembuhan luka dengan faktor lain seperti usia, jangkamasa kencing manis, jangkamasa 
pembedahan,  kawalan kencing manis dan paras hemoglobin. 
 
Kesimpulan: Pesakit-pesakit yang menerima rawatan oksigen di samping rawatan lazim 
untuk luka lapisan epitelium kornea selepas pembedahan vitrektomi merekodkan masa 
penyembuhan yang lebih singkat. Pemberian oksigen kepada pesakit-pesakit dalam golongan 
ini boleh dipertimbangkan untuk membantu mempercepatkan proses penyembuhan luka. 
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ABSTRACT 
 
Introduction: Diabetic patients are prone to developing corneal epithelial defects, either due 
to diabetic keratopathy or as a result of surgery such as pars plana vitrectomy. The healing 
time of corneal epithelial defects in this group of patients may also be delayed due to diabetes. 
Many substances have been investigated to determine their effects on corneal wound healing. 
Oxygen plays a key role as a nutrient for our tissues in the wound healing process. However, 
the effect of systemic oxygen on corneal epithelial wound healing is not known. 
 
Objective: To compare the corneal epithelial healing time between diabetic patients 
receiving and not receiving supplementary oxygen after vitrectomy; and to determine 
whether various factors such as age, duration of diabetes, duration of surgery, glycaemic 
control and haemoglobin level have any influence on corneal epithelial wound healing time. 
 
Methods: A randomised controlled trial was conducted involving diabetic patients planned 
for vitrectomy in Hospital Tuanku Ja’afar Seremban between October 2013 and October 
2014. A 6mm circular corneal epithelial defect was created intra-operatively when there was 
obscuration of surgical field due to corneal haze. Post-operatively, these patients were 
randomised into two treatment groups; “Standard” (standard medical treatment of topical 
Maxitrol™ six-hourly and homatropine 2% six-hourly) or “Oxygen” (standard treatment plus 
systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 
3 days. Time taken for the corneal epithelial defect to heal completely was noted. Other 
parameters recorded were patients’ age, duration of diabetes, duration of surgery, recent 
HbA1C and haemoglobin level. 
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Results: A total of 32 eyes of 32 patients were recruited in this study, consisting of 15 eyes in 
the standard treatment group and 17 eyes in the oxygen group. There were no significant 
differences between the two groups in terms of patient and disease demographics. The mean 
corneal epithelial wound healing time in the oxygen group was significantly faster than those 
in the standard treatment group (3.24 days vs 4.27 days, p = 0.040). Regression analysis 
showed no significant linear relationship between healing time and other factors such as age, 
duration of diabetes, duration of surgery, glycaemic control and haemoglobin level. 
 
Conclusion: Patients who received systemic oxygen therapy on top of the routine post-
operative treatment for corneal epithelial defects after vitrectomy had a faster mean healing 
time. Oxygen administration may be considered in this group of patients to aid the wound 
healing process. 
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Introduction 
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1.1 ANATOMY OF THE CORNEA 
 
1.1.1 BASIC ANATOMY AND HISTOLOGY OF THE CORNEA 
 
The cornea is the most anterior structure of the eyeball that plays an important role in 
refraction of light and protection of the eye from the external environment. Its functions are 
made possible by the highly specialised structural organisation which maintains transparency, 
and the absence of vessels. Being the principal refractive structure of the eye (accounting for 
about 70% of the total refractive power of the eye), the refractive requirements of the cornea 
are met by the regular anterior curvature and optically smooth quality of the overlying tear 
film.  
 
Histologically, the cornea consists of five layers (from anterior to posterior): epithelium, 
Bowman’s layer, stroma, Descemet membrane and endothelium. As recently as 2013, 
however, a novel pre-Descemet layer has been discovered in the human cornea and was 
named Dua’s layer, in honour of the eye researcher who discovered it (Dua et al., 2013). 
 
1.1.2 CORNEAL EPITHELIUM 
 
The corneal epithelium is composed of five to seven layers of stratified non-keratinised 
squamous cells that make up a thickness of about 50 – 60µm (about 10% of the total corneal 
thickness). The layers are made up of distinct cells such as the superficial cells, wing cells 
and basal cells.  
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The corneal epithelium’s most important function is to serve as a barrier between the volatile 
external environment and the internal milieu (Suzuki, 2003). In doing so, the corneal 
epithelium is also crucial for the maintenance of corneal transparency, as any interruption or 
damage to the corneal epithelium will trigger a cascade of events which may result in a 
temporary or even permanent loss of corneal transparency and integrity. Thus, it is important 
to repair any damage to the corneal epithelium as soon as possible. 
  
1.1.3 INNERVATION OF THE CORNEA 
 
The cornea also holds the distinction of being one of the most densely innervated mammalian 
tissues in the body. Richly supplied by sensory and autonomic nerve fibres, the corneal 
innervation is anatomically organised in four levels from the penetrating stromal nerve 
bundles up to the intraepithelial nerve terminals (Müller et al., 2003). The integrity of these 
nerve fibres is crucial in maintaining the refractive and protective functions of the cornea. 
Many ocular and systemic diseases can adversely affect corneal sensory nerves and 
consequently impair their function (Lambiase et al., 1999). 
 
1.2 CORNEAL WOUND HEALING 
 
Under normal circumstances of tissue growth and maintenance, the process requires interplay 
of a number of factors including hormonal, paracrine, neural, vascular, and cellular factors. 
When tissue injury occurs the interaction of these factors, on top of additional factors from 
other sources, become crucial in achieving a normal repair and healing process. (Dayhaw-
Barker, 1995a).  
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The cornea presents an additional challenge to this already complex process. As it is an 
avascular structure that must maintain a highly organised architecture in order to uphold its 
clarity, the wound healing process significantly differs from the normal tissue repair process. 
The nature of the wound, whether is it infectious, chemical, thermal, mechanical or others, 
also greatly influences the outcome of the healing response (Dayhaw-Barker, 1995a). 
 
The corneal wound healing response is a complex process involving a cascade of cytokine-
mediated interactions between the epithelial cells, keratocytes of the stroma, corneal nerves, 
lacrimal glands, tear film, and cells of the immune system (Wilson et al., 2001).  These 
interactions differ greatly between the three main tissues of the cornea, i.e. epithelium, stroma 
and endothelium. Nevertheless, they share a common feature in that the healing process is 
initiated by a loss of communication between cells (Dayhaw-Barker, 1995b).  
 
1.3 CORNEAL EPITHELIAL WOUND HEALING 
 
1.3.1 ROLES OF BASAL CELLS AND LIMBAL STEM CELLS 
 
Basal cells and limbal stem cells play crucial roles in the healing process of any epithelial 
wounds (Suzuki, 2003). The mitotically-active basal cells produce daughter cells that migrate 
anteriorly and differentiate into the wing cells and superficial cells (Beebe and Masters, 1996). 
The ‘X, Y, Z’ hypothesis outlines the three processes involved in maintenance of corneal 
epithelium stability: X, the proliferation of basal epithelial cells; Y, the centripetal movement 
of peripheral cells; and Z, the epithelial cell loss from the cornea surface (Thoft and Friend, 
1983). 
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The replenishment of corneal epithelial cells is also contributed by the presence of stem cells 
located in the limbal region (Dua and Azuara-Blanco, 2000; Lavker et al., 2004; Schlötzer-
Schrehardt and Kruse, 2005). These stems cells, however, enter the cell cycle slowly to 
preserve their proliferative potential and to minimise deoxyribonucleic acid (DNA) 
replication-related errors (Lavker and Sun, 2000). In response to epithelial injury, however, as 
much as 50% of the limbal stem cells may be induced to undergo proliferation (Lehrer et al., 
1998).  
 
The corneal epithelial stem cells derived from the limbus give rise to transient amplifying 
(TA) cells. These cells are capable of multiple instances of cell division. The efficiency is 
amplified by their ability to shorten their cell cycling time from 60 hours under normal 
physiological conditions to 24 hours when there is epithelial injury.  
 
1.3.2 PHASES OF CORNEAL EPITHELIAL WOUND HEALING 
 
The healing of corneal epithelial defects occurs under three distinct but continuous phases: (1) 
migration of neighbouring intact epithelial cells over the defect until the denuded surface is 
covered by a cell monolayer; (2) cell proliferation and stratification resulting in the 
restoration of normal epithelial layer thickness; and (3) differentiation of epithelial cells to 
restore the structured organisation and smooth surface of the corneal epithelium (Steele, 
1999). 
 
The three phases are preceded by a lag phase, in which there is cellular reorganisation and 
synthesis of cytoskeletal proteins (Agrawal and Tsai, 2003).  
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Figure 1.1: Phases of corneal epithelial wound healing (Adapted from Suzuki, 2003). 
 
1.3.3 ROLES OF GROWTH FACTORS IN EPITHELIAL WOUND HEALING 
 
The important phase of cell proliferation in corneal epithelial wound healing is mediated by a 
multitude of growth factors, including epidermal growth factor (EGF), hepatocyte growth 
factor (HGF), keratinocyte growth factor (KGF) and insulin-like growth factor (IGF) (Wilson 
et al., 1994; Imanishi et al., 2000; Zelenka and Arpitha, 2008). These growth factors bind to 
their specific receptors and are subsequently activated or phosphorylated to induce release of 
reactive oxygen species (ROS).  
 
 
Immediately after epithelial abrasion 
Sheet-like movement 
Landslide-like movement 
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1.3.4 REACTIVE OXYGEN SPECIES (ROS) 
 
Reactive oxygen species such as superoxide anion (O
.
2
-
), hydroxyl radical (
.
OH) and 
hydrogen peroxide (H2O2) have been implicated in the oxidative damages that occur in aging 
(Finkel and Holbrook, 2000), malignancies (Hanausek et al., 2003) and degenerative diseases 
such as cataract (Spector, 1995). However, ROS also have other physiological functions 
which are beneficial to the cells generating them. In phagocytic cells of the immune system, 
ROS are essential in the elimination of harmful pathogens (Chanock et al., 1994). In non-
phagocytic cells they have been associated with the stimulatory action of growth factors 
during cell replication (Burdon, 1995; Chao-Wei Chen et al., 2004).  
 
In the corneal epithelium, epidermal growth factor has been demonstrated to induce the 
production of intracellular ROS which in turn was associated with cell proliferation. In 
addition to that, EGF-induced ROS was also found to profoundly affect corneal epithelial cell 
adhesion, migration and surface wound healing (Huo et al., 2009).  
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1.4 NEUROTROPHIC KERATOPATHY 
 
Neurotropic keratopathy is a degenerative corneal disease characterised by the impairment of 
corneal sensitivity associated with epithelial breakdown, a deficiency in the healing process 
leading to corneal ulceration, and subsequent vision loss. It has been classified into three 
stages (Mackie, 2000): 
 
Stage 1: characterised by Rose Bengal staining of the inferior palpebral conjunctival 
surface, a decrease in tear breakup time, increased mucous viscosity and 
punctate epithelial keratopathy.  
 
Stage 2: characterised by epithelial breakdown, which is usually oval or circular in 
shape and often localised in the superior half of the cornea. The defect is 
surrounded by a rim of loose epithelium which become smooth and rolled over 
time. There may be an associated stromal swelling and rarely, anterior 
chamber inflammatory reaction. 
 
Stage 3: characterised by stromal involvement with a corneal ulcer that may progress to 
melting and perforation. 
 
There are many ocular and systemic diseases that can cause neurotropic keratopathy. They 
share the same pathogenetic mechanism, namely the involvement of the trigeminal nerve 
(Lambiase et al., 1999). 
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1.5 DIABETIC KERATOPATHY 
 
Diabetes mellitus, as one of the leading systemic causes of neurotropic keratopathy, has 
gained the attention of many as the global burden of the disease has been profound. While 
abnormalities of the retina and lens secondary to diabetes have been extensively studied, 
corneal disorders due to diabetes (also known as diabetic keratopathy) are increasingly being 
recognised as a significant cause of morbidity associated with diabetes (McNamara, 1997; 
Cisarik-Fredenburg, 2001; Kaji, 2005). It has been estimated that diabetic keratopathy 
occurred in 47 – 64% of diabetic patients during the course of their disease (Schultz et al., 
1981). 
 
The corneal epithelial changes in diabetic patients are increasingly being documented. Their 
corneal epithelial cells are larger in size, more heterogenous in morphology, and are 
irregularly arranged as compared to the corneas of non-diabetics (Tsubota et al., 1991a; 
Tsubota et al., 1991b; Meller et al., 1996). There is also alteration in the thickness and 
interaction between the epithelial basement membrane cells (Taylor and Kimsey, 1981; Azar 
et al., 1992).  Hemidesmosomal attachments onto the epithelial basement membrane is also 
reduced (Tabatabay et al., 1988).  
 
As such, it is not surprising that diabetic patients have an increased risk of developing 
keratopathies such as epithelial fragility corneal epithelial defects, recurrent epithelial 
erosions, decreased sensitivity, abnormal wound healing, increased susceptibility to injury 
and non-healing or infected corneal ulceration (Fowler, 1980; Kabosova et al., 2003; 
Chikama et al., 2007).  
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Corneal sensitivity is also significantly reduced in diabetic patients (Schwartz, 1974). In fact, 
the reduction in corneal sensitivity is a strong predictor of the presence of diabetic peripheral 
neuropathy. The severity of keratopathy has been found to be directly related to the degree of 
peripheral sensation loss (Schultz et al., 1983).  
 
Metabolic and physiological differences also exist between corneas of diabetic and non-
diabetic patients, including altered expression of growth factors (Saghizadeh et al., 2001), 
reduced oxygen uptake (Rubinstein et al., 1990) and increased aldose reductase enzyme 
activity (Akagi et al., 1984).  
 
While the exact mechanism remains elusive, experimental studies have identified that the 
enzyme aldose reductase may be involved in both diabetic keratopathy and reduced corneal 
sensitivity. During hyperglycaemia, accumulation of sorbitol within epithelial cells occurs 
due to the activation of the polyol pathway and increased aldose reductase activity (Akagi et 
al., 1984). Sorbitol causes osmotic stress, which may lead to cellular oedema and damage of 
the corneal epithelial cells and nerves. 
 
There is little doubt that there is a myriad of corneal complications which can potentially 
occur in a diabetic patient. If left unrecognised or untreated early, they may ultimately lead to 
permanent visual loss. 
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1.6 VITREORETINAL SURGERY IN DIABETIC PATIENTS 
 
The complications of diabetes on the eye such as keratopathy and retinopathy inevitably lead 
to an increased incidence of interventions and surgery. The altered corneal sensation plus 
structural changes of the cornea increases the risk of corneal diseases such as infection, 
ulceration and perforation. Meanwhile, diabetic retinopathy is one of the commonest 
indications for vitreoretinal surgery.  
 
It has been established that vitreoretinal surgery can be associated with intraoperative corneal 
epithelial oedema and even late corneal decompensation (Brightbill et al., 1978; Foulks et al., 
1979; Friberg et al., 1984). During surgery, corneal epithelium debridement is sometimes 
necessary to ensure a clear and unobstructed view of the posterior segment. In a survey 
involving 44 active vitreoretinal surgeons with high volume of surgeries in Japan and the 
United States, the average overall debridement rate was 17.4% ± 19.0% (mean ±  standard 
deviation) with a range of 0% to 90% (Friberg et al., 2003).  However, the survey was not 
designed to include data regarding the surgical complexity of the cases or the duration of 
surgery. 
 
Nevertheless, it is safe to assume that the risk of corneal epithelial defects in diabetic patients 
undergoing pars plana vitrectomy is particularly high and presents significant morbidity 
issues in terms of management and further complications.  
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1.7 TREATMENT OF CORNEAL EPITHELIAL DEFECTS 
  
The standard treatment strategy for a non-infected corneal epithelial defect includes infection 
prevention by instillation of prophylactic topical antibiotics, pain relief by oral or topical 
analgesics, and promotion of epithelial wound healing either by patching or therapeutic 
(‘bandage’) contact lenses.  
 
While there are no randomised clinical trials to demonstrate the advantage of prophylactic 
antibiotics use in non-infected epithelial defects, eye surgeons generally do prescribe topical 
antibiotics due to the higher risk of infection in a denuded cornea epithelium, particularly if 
the eye if patched or a bandage contact lens is applied (Dohlman et al., 1973). There are also 
controversies surrounding the use of patching, as some studies and meta-analyses have shown 
that patching does not promote healing and may even have deleterious effects as compared to 
non-patched eyes (Campanile et al., 1997; Flynn et al., 1998; Turner and Rabiu, 2006).  
 
While there are also concerns regarding the use of topical steroids in corneal epithelial 
defects, it has been shown in one study that there is no significant difference in the healing 
time between patients receiving topical steroid (i.e. dexamethasone) and those without 
postoperative topical steroid treatment after vitreoretinal surgery (Yülek et al., 2006). 
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1.7.1 AGENTS USED FOR ACCELERATION OF CORNEAL EPITHELIAL 
WOUND HEALING 
 
There have been an increasing number of studies done to evaluate the safety and efficacy of 
various substances which can be used in the treatment of corneal epithelial defects in diabetic 
patients or animal models. These include the use of topical insulin (Zagon et al., 2007; 
Bastion and Ling, 2013), autologous serum (Schulze et al., 2006), opioid antagonist i.e. 
naltrexone (Zagon et al., 1998) and substance P (Nishida et al., 1996). 
 
1.8 USE OF OXYGEN IN OPHTHALMOLOGY 
 
The use of oxygen in ophthalmology is largely confined to the hyperbaric oxygen therapy 
(HBOT) delivery method. Nevertheless, a growing body of evidence have demonstrated the 
beneficial effects of HBOT on a wide range of ocular conditions (Butler Jr, 1995; Oguz and 
Sobaci, 2008). Among the uses of hyperbaric oxygen therapy in ophthalmic practice include 
occlusive vasculopathies such as central retinal or vein occlusion (Kiryu and Ogura, 1996; 
Krott et al., 1999), diabetic retinopathy (Dumitru, 1992), scleral melting and necrosis after 
antimetabolite or beta irradiation in pterygium surgery (Green and Brannen, 1995; Bayer et 
al., 2001), corneal oedema and anterior segment ischaemia (De Smet et al., 1987; Recupero et 
al., 1992) and ocular infections (Yohai et al., 1994). 
 
The physiological basis of hyperbaric oxygen therapy is essentially hyperoxygenation (or 
hyperoxia), which confers many biochemical, cellular and physiological benefits (Tibbles and 
Edelsberg, 1996; Leach et al., 1998). The rise in the level of oxidants may also act as cell 
messengers in the stimulation of growth factor release in wound healing (Sen et al., 2002). 
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The secondary effects of hyperbaric oxygen include vasoconstriction, fibroblast proliferation, 
immune cell-mediated oxidative killing of pathogens, toxin (clostridial) inhibition, and 
antibiotic (fluoroquinolones and aminoglycosides) synergy (Leach et al., 1998). 
 
1.8.1 OXYGEN IN CORNEAL WOUND HEALING 
 
Oxygen benefits wound healing by several mechanisms, including upregulation of various 
growth factors, downregulation of inflammatory cytokines, improvement in leukocyte 
function and reduction of oedema. Furthermore, it demonstrates antibacterial effects and at 
the same time supports angiogenesis and new tissue ingrowth (Sheikh et al., 2000; Wright, 
2001). 
 
While there are more studies examining the use of hyperbaric oxygen therapy (HBOT) in 
ophthalmology, there have been no studies utilising other methods of oxygen therapy until 
recently. A pilot study done in Iran (Sharifipour et al., 2011), in which systemic oxygen 
therapy was delivered via face mask at 10 litres per minute twice daily in acute ocular 
chemical or thermal injury. The eyes of subjects receiving systemic oxygen therapy showed 
improvement in limbal ischemia, acceleration of epithelialisation, increase in corneal 
transparency, and decrease in corneal vascularisation. The likely end-result of these effects is 
improvement in visual acuity and reduction in complications. 
 
There is no evidence of direct risk from administration of systemic oxygen via a face mask to 
the ocular structures. The likely risks of this route of oxygen administration are towards the 
other structures such as drying of nasal and pharyngeal mucosa, and skin irritation. It may 
also pose a fire hazard risk. 
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This study aims to examine the effects of systemic oxygen as a supplementary therapy on the 
healing of corneal epithelial wounds in post-vitrectomy diabetic patients. Due to the ease of 
administration of oxygen and the potential effect of oxygen therapy, the use of supplemental 
oxygen therapy for the treatment of corneal epithelial wound post-vitrectomy will perhaps 
accelerate the healing process in diabetic patients. It is hoped that by accelerating the closure 
of an epithelial wound in this group of patients, the risk of complications such as recurrent 
erosions, non-healing wounds and infective keratitis may be further reduced in these already 
at-risk corneas. 
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2.1 GENERAL OBJECTIVE 
 
To study the effects of systemic oxygen supplementary therapy on corneal epithelial wound 
healing time after pars plana vitrectomy in diabetic patients. 
 
2.2 SPECIFIC OBJECTIVES 
 
2.2.1 To compare the corneal epithelial wound healing time between diabetic patients 
receiving and not receiving supplementary oxygen after vitrectomy. 
 
2.2.2 To determine the confounding factors affecting corneal epithelial wound healing time 
in diabetic patients post-vitrectomy. 
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3.1 STUDY DESIGN 
 
Prospective interventional randomised clinical trial 
 
3.2 POPULATION, TIME AND PLACE OF STUDY 
 
Study sample:  Diabetic patients who underwent pars plana vitrectomy in 
Hospital Tuanku Ja’afar, Seremban who met the inclusion and 
exclusion criteria. 
 
Study subjects: Diabetic patients who underwent pars plana vitrectomy in 
Hospital Tuanku Ja’afar, Seremban and consented to take part 
in the study. 
 
Period of study: 31 October 2013 – 31 October 2014. 
 
Place of study: Department of Ophthalmology, Hospital Tuanku Ja’afar, 
Seremban, Negeri Sembilan Darul Khusus. 
 
 
 
 
20 
 
3.3 SAMPLING AND SAMPLE SIZE 
 
3.3.1  SAMPLING METHOD AND RANDOMISATION 
 
A purposive sampling method was used in this study. Patients were allocated a number 
determined from a computer software-generated (QuickCalc, GraphPad Software Inc., 
California) table of random numbers and were divided into two treatment groups: 
 
 “Standard” group (odd numbers) – Standard medical treatment: topical Maxitrol(R)  
(Alcon Labs, USA) consisting of an antibiotic-steroids sterile suspension of 
Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate), and topical 
Isopto® Homatropine 2% (Alcon Labs, USA) 
 
 “Oxygen” group (even numbers): Standard medical treatment plus systemic oxygen 
via face mask given at 10 litres/min, one hour per session and twice daily (12 hours 
apart). 
 
3.3.2 SAMPLE SIZE CALCULATION 
 
Sample size calculation was done using the PS Power and Sample Size Calculation software 
version 3.1.2 (January 2009, Tennessee, USA; Vanderbilt University). The power of the study 
was set at 90%, while the probability of error (α) was set at 0.05.  
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As the main objective of this study was to compare the mean healing time between two 
treatment arms, calculation of sample size using the software was done under the t-test mode. 
 
To the best of our knowledge, there had not been any similar studies conducted to evaluate 
the effects of systemic oxygen on corneal epithelial wound healing.  
 
Therefore, the difference in mean (δ) and the standard deviation (σ) of 2.8 days and 2 days 
respectively were taken from a study that had an almost similar design but used autologous 
serum as its treatment under study (Schulze et al., 2006). 
 
To account for the possibility of a 20% drop-out rate in this study, the sample size for each 
treatment arm was therefore: 
12 + (
20
100
% x 12) = 12 + 2.4 = 14 
A minimum sample size of 14 patients were required in each treatment group to obtain a 
study power of 90% at an alpha of 0.05. 
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3.4 SELECTION CRITERIA 
  
3.4.1 INCLUSION CRITERIA 
1. Diabetic patients indicated for pars plana vitrectomy  
2. Epithelial debridement performed during pars plana vitrectomy 
3. Age 18 years and above 
 
3.4.2 EXCLUSION CRITERIA 
1. Known case of ocular surface or corneal disease. 
2. History of eye surgery within one month from the date of pars plana vitrectomy 
3. Pre-existing primary or secondary glaucoma e.g. open angle or angle closure 
glaucoma, ghost cell glaucoma 
4. Patients with chronic obstructive airway disease 
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3.5 ETHICAL BOARD APPROVAL 
 
The study received approval from the Human Research Ethics Committee, Universiti Sains 
Malaysia on 17
th
 October 2013 (Reference number: USM/JEPeM/269.3 (2)) and the Medical 
Research and Ethics Committee, Ministry of Health Malaysia on 8
th
 October 2013 
(Reference: (6) dlm. KKM/NIHSEC/800-2/2/2 Jld 3 P13-368).   
 
The study was also registered with the National Medical Research Registry 
(http://www.nmrr.gov.my) (Reference: NMRR-13-449-15617) and also with 
ClinicalTrials.gov (http://www.clinicaltrials.gov) (ID: NCT02344732). 
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3.6  DEFINITION OF TERMS 
 
3.6.1  CORNEAL EPITHELIAL DEFECT 
 
It is a defect in the corneal epithelium that, in this study, was induced intra-operatively by 
means of an iatrogenic corneal epithelial debridement. The area of debridement was marked 
using a 6mm corneal trephine imprint, and debridement was performed using the Kimura 
spatula (McGrath and Lee, 2014). 
 
3.6.2 CORNEAL EPITHELIAL WOUND HEALING 
 
Corneal epithelial wound healing is a complex process involving three distinct components of 
cell migration, cell proliferation and cell adhesion (Dua et al., 1994).  
 
3.6.3 SYSTEMIC OXYGEN THERAPY 
 
Systemic oxygen therapy is the administration of oxygen to the patients delivered via nasal 
prongs, face mask, high-flow mask or endotracheal tube (Bateman and Leach, 1998). In this 
study, the systemic oxygen therapy was administered using a face mask. 
 
3.6.4 PARS PLANA VITRECTOMY 
 
Pars plana vitrectomy is a surgical procedure involving the removal of the vitreous humour 
approached via the pars plana (Young and Shea, 1977). 
 
